Background: Diabetic ketoacidosis (DKA) is one of the serious acute complications of diabetes. Euglycemic diabetic ketoacidosis (EDKA) is one of the side effects associated with sodium-glucose cotransporter 2 (SGLT2) inhibitors. It is very difficult to diagnose due to the absence of hyperglycemia, thereby leading to delayed diagnosis and treatment.
Case: The author did a case of a diabetic patient who underwent coronary artery bypass grafting (CABG) and developed EDKA during the intraoperative period, most likely due to the use of dapagliflozin.
Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism 2016;65(4):507–521. DOI: 10.1016/j.metabol.2015.12.007
Munro JF, Campbell IW, McCuish AC, et al. Euglycaemic diabetic ketoacidosis. Br Med J 1973;2(5866):578–580. DOI: 10.1136/bmj.2.5866.578
Qui H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev 2017;33(5). DOI: 10.1002/dmrr.2886
Singh M, Kumar A. Risks associated with SGLT2 inhibitors: an overview. Curr Drug Saf 2018;13(2):84–91. DOI: 10.2174/1574886313666180226103408
Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21(5):512–517. DOI: 10.1038/nm.3828
Gelaye A, Haidar A, Kassab C, et al. Severe ketoacidosis associated with canagliflozin (Invokana): a safety concern. Case Rep Crit Care 2016;2016:1656182. DOI: 10.1155/2016/1656182
Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38(9):1638–1642. DOI: 10.2337/dc15-1380
